chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. The patient's relevant medical history and concomitant medication were not reported. In 2015 (reported for all vaccines as since 14-MAY-2015, which was the date the excursion occurred), the patient was vaccinated with a dose of (Oka/Merck) PROQUAD (dose and route were not reported) which underwent supported temperature excursions. The patient might have received the following lot numbers and expiration dates of (Oka/Merck) PROQUAD: Lot # L002419 with expiration ate 23-JUL-2016 or lot # reported as L005293 with expiration date 17-AUG-2016. No adverse effects were reported. No PQC (product quality complaint) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
This spontaneous report was received from a physician, and it refers to a 37 year old male patient. Information regarding the patient's medical history, concurrent conditions and concomitant medications was not provided. On 22-MAY-2018, the patient was inadvertently vaccinated with a dose of SHINGRIX for prophylaxis (dose, route of administration, lot number and expiration date were not reported) instead of Oka/Merck VARIVAX for prophylaxis (dose, route of administration, lot number and expiration date were not reported) (Wrong drug administered), from an unspecified pharmacy, also on 29-MAY-2018 the patient was vaccinated with one adult dose of Hepatitis A Vaccine, Inactivated (manufacturer unknown) 50/1 U/ml, for prophylaxis (dose, route of administration, lot number and expiration date were not reported) from the local health department. The vaccines were indicated for immigration purposes. On an unknown date, the patient was found to have low titers for varicella and hepatitis A (varicella titer was <135) (Antibody test abnormal), as a result of an unspecified test performed. The physician reported that the plan was to vaccinate the patient with varicella and hepatitis A. No adverse effects reported. No further information was provided. The outcome of the antibody test abnormal and the causal relationship between the event and therapy with VAQTA were not reported.
Swelling in my neck later determined to be Lymphocytes.   Surgery was required to remove them.
fatigue; joint/muscle pains all over; joint/muscle pains all over; Nausea; This is a spontaneous report from a contactable consumer or other non-health care professional.   A 63-years-old non pregnant female patient (not pregnant at the time of vaccination) received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: EN6200), dose 1 via an unspecified route of administration, administered in Arm Left on 25Feb2021 19:00 (at the age of 63-year-old) as dose 1, single for covid-19 immunisation. The patient medical history included migraines, degenerative arthritis in the neck and mild asthma from an unspecified date. The patient's concomitant medications included thyroid (ARMOUR THYROID), Lovastatin (LOVASTATIN), acetylsalicylic acid, caffeine, paracetamol Excedrin (migraine medicine) for migraine and naproxen sodium (ALEVE) for degenerative arthritis received within 2 weeks of vaccination. The patient did not received any other vaccines within 4 weeks prior to the covid 19 vaccine. The patient had not been diagnosed with COVID-19 prior to vaccination and had not been tested since the vaccination. The patient had no known allergies. On 26Feb2021, 1:00 AM the patient experienced fatigue, joint/muscle pains all over, nausea. The patient took treatment for the adverse events over the phone call to nurse practitioner. The clinical outcome of the events was recovered on an unspecified date on Feb2021.  No follow-up attempts are needed. No further information is expected.
I was disappointed after the booster that my coughing did not stop; I was disappointed after the booster that my coughing did not stop; I was disappointed after the booster that my coughing did not stop; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program (005570). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "dry cough" (unspecified if ongoing), notes: I have had a dry cough for about 18 years that no one has been able to find a cure for. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 2), for COVID-19 immunization; Bnt162b2 (DOSE 1), for COVID-19 Immunization. The following information was reported: IMMUNISATION (non-serious), EMOTIONAL DISORDER (non-serious), outcome "unknown" and all described as "I was disappointed after the booster that my coughing did not stop"; COUGH (non-serious), outcome "not recovered".  Additional information: When patient had first Pfizer vaccine for COVID-19 within hours, stopped coughing all together. A few months after the 2nd dose the coughing slowly started returning. The patient was disappointed after the booster that coughing did not stop.   The lot number for bnt162b2 was not provided and will be requested during follow up.
My blood pressure has always been normal, 120/80 max.  .  It was normal on the day of the booster shot.  Two days later, I visited Dr for the first time two days later and my blood pressure was about 181/91 .  It did not occur to me at the time that there may be a connection.
This case was reported by a nurse and described the occurrence of a possible allergic reaction in a 4 year old male pt who received DTAP (Infanrix) for prophylaxis. On an unspecified date, the pt received the 5th dose of Infanrix (Lot  # DTPA586B9).  On 04/01/03, at an unspecified time post-immunization, the pt experienced a possible allergic reaction characterized by swelling and redness at the injection site. The pt was seen by the physician, who prescribed Zyrtec. The event resolved after an unspecified period of time. The reporting nurse considered the event was related to vaccination with Infanrix.
I experienced after lunch time, I felt I was like drink, slurring my words. on 01-28-2021, the left side of my face was tingly and numb. When I went to work my coworkers noticed my left eye and face was dropping. I also started to drag my left leg.  I went to urgent care and was treated as stroke like symptoms.  I was admitted for one day at urgent care. My symptoms were gone within the next day.  I have not had any symptoms since then.
Aches all over; Aches / especially in the back; Aches / legs; Fatigue; Slight fever; Headache; This case was reported by a consumer and described the occurrence of general body pain in a adult patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 28th December 2020 14:00, the patient received the 2nd dose of Shingles vaccine. In December 2020, less than a day after receiving Shingles vaccine, the patient experienced general body pain, back pain, leg pain, fatigue, fever and headache. The patient was treated with naproxen. On an unknown date, the outcome of the general body pain, back pain, leg pain, fatigue and fever were recovered/resolved and the outcome of the headache was unknown.   It was unknown if the reporter considered the general body pain, back pain, leg pain, fatigue, fever and headache to be related to Shingles vaccine.  Additional information was provided as follows: The age at vaccination was not reported. The age group was selected as adult as per the vaccine indication. On the day of reporting, the patient  woke up with aches all over especially in the back and legs, fatigue, headache and slight fever (100.3 degree celsius) was coming down. The patient stated, the temperature was back to normal and ache and fatigue was gone. The patient took Naproxen and had some relief. The patient was asking how to differentiate the symptoms as he/she was concerned that the side effects mimic Covid 19 symptoms. The consent to follow up was requested.
After the 2nd covid vaccine she noticed her left armpit swelling; the arm swelling after the first two vaccines; This is a spontaneous report received from contactable reporter(s) (Nurse). The reporter is the patient.  A 73-year-old female patient received BNT162b2 (BNT162B2), on 12Mar2021 as dose 2, single (Lot number: EN6208) at the age of 73 years, in left deltoid for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: BNT162b2 (DOSE 1, SINGLE; lot number:EN6198; anatomical location: Deltoid Left), administration date: 20Feb2021, when the patient was 73-year-old, for Covid-19 Immunization, reaction(s): "the arm swelling after the first two vaccines". The following information was reported: SWELLING (non-serious), outcome "not recovered", described as "After the 2nd covid vaccine she noticed her left armpit swelling"; PERIPHERAL SWELLING (non-serious), outcome "not recovered", described as "the arm swelling after the first two vaccines". The events "after the 2nd covid vaccine she noticed her left armpit swelling" and "the arm swelling after the first two vaccines" required physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of swelling, peripheral swelling.  Additional information: It was also reported that there were no other conditions. NDC number was unknown and there was no other product. Patient height was 5 feet 2.5 inches. After the 2nd covid vaccine she noticed her left armpit swelling and read that was happening so that is why all subsequent ones she did on her left arm and it just feels different under her arm now and was swollen; her doctor sent her for an ultrasound and nothing was detected as amiss but the swelling was ongoing now and was squishy and feels different than the other side. The ultrasound shows as nothing swollen for nodes or lymph nodes at that time and she did not remember when the ultrasound was but it was probably a couple of months after the doses of vaccine. For being diagnosed with covid and the armpit swelling after the covid vaccines, states it was medically significant because people want to get treatment if it was discerned to being enlarged lymph nodes or breast cancer and it was important to get these statistics. Had no treatment for the reported event but just had the ultrasound for the arm swelling after the first two vaccines and that was it just to make sure that it was not cancerous lumps.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201343399 same reporter/patient with different AE/product;
patient says he had chills the night of vaccination on 11/6/2021, then vomitting several times and diarrhea, still expiriencing diarrhea
dose was given after expiration date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (dose was given after expiration date) in a 23-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 043B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Oct-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (dose was given after expiration date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (dose was given after expiration date) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication of the patient was not reported.  The vial was placed in refrigerator on 17-Nov-2021. It was reported that the expired lots were administered due to the confusion with expiry date printed in the carton and the expiration date when the QR code was scanned. The vials did not undergo temperature excursion. The patient did not experience any adverse event.  No treatment information was provided by the reporter.
DEEP MUSCLE PAIN PRIMARILY IN FLEXORS; This spontaneous report received from a patient concerned a 52 year old of unspecified sex. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included: The patient had no known allergies. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1808986, and expiry: 02-OCT-2021) dose was not reported, administered on 27-SEP-2021 for prophylactic vaccination. No concomitant medications were reported. On 03-OCT-2021, the patient experienced deep muscle pain primarily in flexors. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from deep muscle pain primarily in flexors on 03-OCT-2021. This report was non-serious.
I exp rash (not bumpy), itchy in the area of injection site spreaded out to elbow lasting a day or two. I contacted my doctor on Friday the nurse advised me to take Benadryl every 4 hrs. When I stopped taking it on Sunday it came back spoke with doctor on Monday stated it was a autoimmune prescribed medication.
This case was reported by a pharmacist via call center representative and described the occurrence of flu like symptoms in a 69-year-old male patient who received SHINGRIX (batch number T5242, expiry date 31st March 2020) for prophylaxis. Concurrent medical conditions included back pain. On 2nd June 2018, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. On 3rd June 2018, 1 days after receiving SHINGRIX, the patient experienced flu like symptoms, lethargic, fever, pallor, weight loss, gastric disorder and tiredness. On an unknown date, the outcome of the flu like symptoms, fever and pallor were recovered/resolved and the outcome of the lethargic was not recovered/not resolved and the outcome of the weight loss, gastric disorder and tiredness were unknown. The reporter considered the flu like symptoms, lethargic, fever, pallor and weight loss to be almost certainly related to SHINGRIX. It was unknown if the reporter considered the gastric disorder and tiredness to be related to SHINGRIX. Additional details were provided as follows: The health care professional reported that the patient received SHINGRIX on left arm. The following day, the patient experienced flu like symptoms, was very pale like white as a ghost and had fever (which resolved the following day), weight loss of 1 pound, the stomach was not right and the patient was lethargic. Everything was resolved at that point except for the lethargy. The health care professional stated that the patient could not seem to shake it off from being so tired. The health care professional mentioned that, the patient was in the heat outside the day he received the vaccine. The patient was the health care professional technician at the pharmacy. The reporter and the patient work together.
Information has been received from a physician concerning a 2 month old male who on approximately 03-MAR-2008 3-4 weeks ago, was vaccinated PO with his first 2.0 ml dose of Rotateq.  On approximately 10-MAR-2008 a week after vaccination, the patient experienced diarrhea.  The infant was seen in the office twice for the same symptom.  Subsequently, the patient recovered.  There was no product quality complaint.  Additional information has been requested.
No symptoms until second vaccine. After receiving the second vaccine (2/10/2021 at 10am) my lips began to swell around 12:30pm.  In case of an allergic reaction I took 25mg of Benadryl and the swelling went down by 6pm. The next morning (2/11/2021) I noticed a couple of hives on my face so I took the Benadryl again that day and it cleared up within a couple of hours. Also was very fatigued and had body aches for 2 days after the second vaccine.
small, firm, tender papule @ site of vax inject; some tenderness, swelling & induration of the deltoid muscle;
pt recv vax 18DEC95 & 29MAR97 pt devel greater than 50 lesions that were located primarily on trunk w/a few located on neck;
pt recvd vax;bilateral otitis med;sz,fever;devel delay,congenital hypotonia;to er;was flaccid,not responsive;resp distress;PH 7.170,PCO2=62;PO2=202;base excess of 6-6;CBC showed WBC=23.2;glucose inc to 205;8 L of O2 by mask x resp acidosis;
Information has been received from a health professional concerning a female who on 05 SEP-2007 was IM vaccinated with her first dose of GARDASIL (654539/0242U). On 21-Nov-2007 the patient was IM vaccinated with her second dose of GARDASIL (lot number 654519/0742U). Subsequently the patient experienced nausea and dizziness after both doses. The patient sought unspecified medical treatment which included the patient's mother calling the physician. Subsequently, the patient recovered from nausea and dizziness. Additional information has been requested. This is in follow-up to rep(s) previously submitted on 4/14/2008.  On 01-Apr-2008 the patient reported receiving her third dose of GARDASIL (lot number 654540/1290U).  Concomitant medication included vaccination with meningococcal ACYW conj vaccine (dip toxoid) on 05-Sep-2007.  Follow up information clarified the initial discrepancy of the third dose date.  It was also reported that when the patient received her third dose, she was placed in a supine position and the patient did not feel as if she were going to pass out.
Assessment and Plan:  77 y.o. female patient of, MD with history of respiratory failure, CHF, A-fib, CAD, CKD, COPD, DM 2, HLD, PulmHTN presented to Medical Center with dyspnea and chest pain.     Acute on chronic respiratory failure with hypoxia Covid-19 Virus Infection Date of onset of symptoms: 2/17/2023 Symptoms present on admission: Dyspnea, chest pain, cough Date of covid positive test: 2/18/2023 Vaccination status: vaccinated Platelets: 115 (2/18) admitted with COVID-19 Baseline 102-115 Imaging: CT dissection without evidence of dissection or PE Oxygen requirements on admission: 4 L Current oxygen requirements: 2 L which is her baseline Medical therapy: steroids continued for 5 more days, will stop remdesivir  Continue Symbicort, DuoNebs, and PRN albuterol PT/OT consulted: Pt declined consult   Chest pain CAD Recent work-up including PET perfusion in November with stable CAD Pain in setting of new COVID infection Troponin minimally elevated at 16, trended flat to 15 EKG without evidence of acute ischemia Monitor symptoms   Abnormal Urinalysis 15 WBC/hpf in ED Denies symptoms of UTI   Hypertension BPs in the ED up to 218/86 with wide fluctuations Resume home antihypertensives  COPD Without acute exacerbation Scheduled Duonebs and PRN Albuterol Continue Symbicort   Prediabetes A1c 5.7 off medications Monitor glucose while on steroids, initiate SSI if needed   HLD Continue home pravastatin   A-fib Paroxysmal Continue metoprolol for rate control Sinus on admission Not anticoagulated   CKD Creatinine stable on admission   Chronic HFpEF Clinically approximately euvolemic Continue home Bumex EF 62% with grade 2 diastolic dysfunction on most recent echo
Patient had dizziness after the shot. Felt better left the health department. Went to school. Called mom from school went to Dr. office with complaints of dizziness near syncope, rash around mouth, extremities felt heavy.
It was reported that a pt rec'd a Menomune A/C/Y/W-135 vaccination on 9/27/01. She presented to Hlth svcs unspecified date with complaint of headache on a scale of 10 to be an 8. she is diabetic and states her blood sugars have been running high since the Menomune vaccine was given. Doctor evaluated her but did not find a reason for her headaches. Pt states that Advil has only alleviated headaches for a very short time, the last time taken alleviation lasted for only 45 minutes.
Shallow breathing; my pulse was very fast; Tenderness at the injection site; Pain at the injection area; Had expected symptoms; Had diarrhea lasted for full day and the following day; Fatigue; Nausea; Fever; Experienced rapid pulse; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Had expected symptoms), DIARRHOEA (Had diarrhea lasted for full day and the following day), HEART RATE INCREASED (Experienced rapid pulse), HYPOPNOEA (Shallow breathing) and HEART RATE INCREASED (my pulse was very fast) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included METOPROLOL for an unknown indication.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2021, the patient experienced HEART RATE INCREASED (Experienced rapid pulse). On 02-Mar-2021, the patient experienced VACCINATION COMPLICATION (Had expected symptoms), DIARRHOEA (Had diarrhea lasted for full day and the following day), FATIGUE (Fatigue), NAUSEA (Nausea) and PYREXIA (Fever). On 04-Mar-2021, the patient experienced HYPOPNOEA (Shallow breathing), HEART RATE INCREASED (my pulse was very fast), VACCINATION SITE PAIN (Tenderness at the injection site) and VACCINATION SITE PAIN (Pain at the injection area). The patient was treated with PARACETAMOL (TYLENOL) for Fever, at an unspecified dose and frequency. At the time of the report, VACCINATION COMPLICATION (Had expected symptoms), DIARRHOEA (Had diarrhea lasted for full day and the following day), HEART RATE INCREASED (Experienced rapid pulse), HYPOPNOEA (Shallow breathing), HEART RATE INCREASED (my pulse was very fast), FATIGUE (Fatigue), NAUSEA (Nausea), PYREXIA (Fever), VACCINATION SITE PAIN (Tenderness at the injection site) and VACCINATION SITE PAIN (Pain at the injection area) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
After one week, I started getting burning on the backs of my arms, leading up to my shoulders.  One day it would burn, the next it wouldn't.  As the weeks went on, the burning became more intense and the burning seemed to travel throughout my body - as of today, May 4,, 2001, it is a constant burning - sometimes on the tops of my arms, the tops of my legs, my chest, my back.
feeling pain in the area of my gluteus; felt muscle pain all over my body; This case was reported by a consumer and described the occurrence of generalized muscle aches in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of fatigue (1st dose received in August 2019, refer linked case US2020AMR015673).   On 23rd January 2020, the patient received the 2nd dose of Shingrix. On 24th January 2020, 1 days after receiving Shingrix, the patient experienced generalized muscle aches. On 25th January 2020, the patient experienced buttock pain. On an unknown date, the outcome of the generalized muscle aches was recovered/resolved and the outcome of the buttock pain was not recovered/not resolved.   It was unknown if the reporter considered the generalized muscle aches and buttock pain to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported.  The age group was not reported but it was selected as adult as per the vaccine indication. The patient experienced muscle pain all over body, then it subsided. On Saturday 2 days after receiving vaccination, the patient started feeling pain in the area of gluteus. On Monday the patient  was still feeling this pain.
Patient given2 doses of Moderna Booster for 2nd dose.   Error but no reaction; action taken at the time of administration.
Dizziness, Headache, Myalgia, NauseaVomiting, FATIGUE Narrative:
Sore Left arm with pain radiating down Left arm upon initial injection. Stiffness and pain Left shoulder for two days with decreased range of motion. Initial improvement 01/15/21 with reoccurrence of pain on motion and stiffness on 01/18/21